Tools

Which psychedelic therapy might fit you?

A short, client-side decision tree that takes your goals, medical considerations, and legal constraints and suggests which therapy the evidence and access landscape supports exploring first. Not medical advice.

Depression treatment path

A practical next-step guide for treatment-resistant depression: compare Spravato, IV/IM ketamine, at-home ketamine, psilocybin trials, and Oregon/Colorado psilocybin services by legality, insurance, evidence, and what to ask at the first appointment.

At-home ketamine safety checklist

A safety-first guide to what is actually available at home: compounded oral/sublingual ketamine via telehealth, why Spravato is never take-home, what remote integration can and cannot do, and when at-home treatment is the wrong starting point.

Find a ketamine therapy provider

Curated directory of US ketamine therapy providers — at-home telehealth programs, in-clinic IV/IM infusion networks, and the Spravato (esketamine) REMS network — with vetting guidance.

Find a psychedelic-integration therapist

A curated meta-directory of the established psychedelic-therapist training programs (Fluence, CIIS, Polaris, IPI, Naropa, Sage, MAPS) whose alumni directories are the credible starting points.

Find a legal psychedelic retreat

Oregon Measure 109 and Colorado Prop 122 licensed service centers, plus the more medically-structured international operators for ayahuasca, ibogaine, and 5-MeO-DMT. Includes a retreat vetting checklist.

Legal psilocybin booking checklist

Step-by-step checklist for booking legal psilocybin services: verify Oregon or Colorado licenses, distinguish legal service centers from decriminalized possession, estimate total cost, screen facilitators, and plan preparation and integration.

Psychedelic Legalization Tracker

A running, auto-updated log of psychedelic legalization moves — new laws, decriminalizations, reschedulings, trial funding, and court rulings across US states and other countries, each linked to its source.

Psychedelic legal status by US state

Plain-English reference for where each state stands on therapeutic access, decriminalization, and active legislation. Filterable by reform type.

Psychedelic Legal Status Map of the United States

National overview of where every US state stands on psilocybin, MDMA, DMT, ibogaine, and ketamine. Four-tier ranking, clickable state grid, and 2026 reform watchlist.

Find Psychedelic Clinical Trials: How to Volunteer

How to find and apply for psychedelic clinical trials: psilocybin, MDMA, ibogaine, DMT, and ketamine. Registry links, institution-specific portals, eligibility criteria, what participation involves, and how participants are protected.

Ceremony readiness quiz

A 12-question self-assessment that scores your readiness for a psychedelic ceremony across medical, psychological, logistical, and integration dimensions. Not a clearance, not medical advice.

Trauma trigger to healing map

Pick a common trigger (criticism, abandonment, conflict, shame) and see the four F's response it usually maps to, what wound it points to, and the integration practices that support healing.

Psychedelic medication safety checker

An interactive screener: enter your prescriptions and supplements and see typical clinical-trial washout windows and the high-risk combinations. Educational only — always coordinate with your prescriber.

MDMA Prescription Authorized in New Zealand: Regulatory and Clinical Implications

New Zealand has authorized a psychiatrist to prescribe MDMA, transitioning the drug from research to clinical use. This development presents new opportunities and challenges for clinicians, regulators, and the emerging psychedelic industry.

Sep 05, 2026

MDMA Prescribing for PTSD: US Federal Policy Breakthrough

MDMA is now federally prescribable for severe PTSD in the US, following FDA approval. This policy shift enables regulated psychedelic therapy, prompts new research, and raises questions on safety, access, and payer coverage.

Sep 05, 2026

Stakeholder Attitudes Toward Psychedelic Therapy in Ireland: 2026 Survey Insights

A newly published national survey of Irish stakeholders offers early data on attitudes toward psychedelic-assisted therapy, revealing both enthusiasm and significant barriers. These findings may shape future policy, research, and clinical adoption in Ireland.

Sep 04, 2026

Synapto-Nuclear Signaling in ALS: Implications for Neuroplasticity Research

A new preclinical study shows that defective synapto-nuclear signaling underlies motoneuron vulnerability in ALS and that enhancing cAMP/PKA signaling can restore function in a mouse model, offering insights for future neuroplasticity research.

Sep 04, 2026

EEG Study Reveals Psilocybin's Distinct Acute and Sub-Acute Effects in Healthy Adults

A 2026 controlled EEG study finds that psilocybin’s long-term positive effects may be predicted by sub-acute brain activity changes, not just acute experiences. This insight could reshape clinical trial endpoints and patient selection in psychedelic research.

Sep 04, 2026